Publication | Open Access
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer
30
Citations
20
References
2019
Year
A diverse population of patients with mPAC that progressed on gemcitabine-based therapy benefited from nal-IRI+5-FU/LV versus 5-FU/LV, potentially helping guide treatment decisions for challenging cases.
| Year | Citations | |
|---|---|---|
Page 1
Page 1